Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Effects on fertility

Effect on fertility: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
1 000 mg/kg bw/day
Study duration:
subacute
Species:
rat
Quality of whole database:
Reliable screening study providing multiple endpoints.
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available
Additional information

The effects of Fatty acids, C18-unsatd., dimers, oligomeric reaction products with tall-oil fatty acids and triethylenetetramine on fertility have been investigated in a combined repeated dose/reproductive screening toxicity study conducted according to OECD Test Guideline 422 (Perks, 2013).

In the study groups of male and female Crl:WI(Han) rats (10 animals/group) were administered with the test substance orally by gavage, at dose levels of 100, 300 and 1000 mg/kg bw/day. Dose levels were selected based on the results of a 14-day range finding study. Male rats were dosed once daily for two weeks prior to pairing, during the pairing period and a further two weeks before necropsy. Males were treated for a minimum of 6 weeks prior to necropsy. Female rats were dosed for two weeks prior to pairing, during pairing and until Day 4 post-partum, inclusive at total of approximately 7 weeks. The females were allowed to litter and rear their offspring to Day 4 post-partum.

There were no treatment related deaths during the study. No treatment-related clinical signs, changes in bodyweight gains, histopathological changes or functional changes were observed in the study. The No-Observed-Adverse-Effect-Level (NOAEL) for the general or systemic toxicity in male and female rats was considered to be 1000 mg/kg bw/day (i.e the highest dose tested).

 

No developmental effects, effects on reproductive parameters or treatment-related signs of systemic toxicity were observed in the study. No treatment-related effects were observed on mating, fertility or fecundity indices; the majority of animals mated within one oestrous cycle. No treatment-related adverse effects were observed on gestational length, the number of implantation sites or pups born, pup survival or body weight gain. Pup necropsy data were unremarkable. Based on this study, The No-Observed-Adverse-Effect-Level (NOAEL) for the effects of the substance on fertility in male and in female rats and for developmental toxicity was considered to be 1000 mg/kg bw/day (i.e. the highest dose tested).

The findings from a proposed 90-day repeated dose oral toxicity study and a pre-natal developmental toxicity study will provide a further characterisation of the reproductive hazard potential of Fatty acids, C18-unsatd., dimers, oligomeric reaction products with tall-oil fatty acids and triethylenetetramine.

In accordance with Column 2 of Annex X of the REACH regulation, a waiver is proposed for the two-generation reproductive toxicity study. No adverse effects or indication of systemic exposure were observed in a combined repeated dose toxicity with reproduction/developmental toxicity screening test (OECD 422) at dose levels up to and including the limit dose. Also, according to Lipinski’s Rule of Five, the substance is not predicted to be bioavailable (OECD QSAR Toolbox). No additional testing is therefore considered necessary on scientific grounds and in the interests of avoiding unnecessary animal testing in accordance with EU Directive 86/609/EEC.


Short description of key information:
No evidence of an effect on the reproductive organs was seen in a combined repeated dose and reproductive/developmental screening study (OECD 422) in rats after repeated oral doses upto 1000 mg/kg bw/day. The findings from a proposed 90-day repeated dose oral toxicity study and a pre-natal developmental toxicity study will provide a further characterisation of the reproductive hazard potential of Fatty acids, C18-unsatd., dimers, oligomeric reaction products with tall-oil fatty acids and triethylenetetramine.

Justification for selection of Effect on fertility via oral route:
Sole study providing data from a guideline compliant study.

Effects on developmental toxicity

Description of key information
A pre-natal developmental toxicity study using Fatty acids, C18-unsatd., dimers, oligomeric reaction products with tall-oil fatty acids and triethylenetetramine in the rat (OECD Test Guideline 414) is proposed in order to evaluate the developmental hazard potential of the substance.
Effect on developmental toxicity: via oral route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available
Additional information

No effects on developmental parameters were observed in a combined repeated dose and reproductive/developmental toxicity study conducted using Fatty acids, C18-unsatd., dimers, oligomeric reaction products with tall-oil fatty acids and triethylenetetramine following oral doses upto 1000 mg/kg bw/day (Perks, 2013). Based on this study, the NOAEL for developmental toxicity was considered to be 1000 mg/kg bw/day (i.e. the highest dose tested)

A pre-natal developmental toxicity study using Fatty acids, C18-unsatd., dimers, oligomeric reaction products with tall-oil fatty acids and triethylenetetramine (OECD Test Guideline 414) is proposed in order to evaluate the developmental hazard potential of the substance.

Justification for classification or non-classification

No classification is proposed: relevant data are not available.

Additional information